Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095621 | 0.94 | ALDH1A1 (0.56) | ALDH1A1TSHRHTTKDM4ETAS1R3 | |
| SCHEMBL6639886 | 0.84 | TSHR (0.44) | ALDH1A1TSHRHTTKDM4ECNR1 | |
| SCHEMBL6637090 | 0.82 | TRPV1 (0.43) | ALDH1A1TSHRHTTCNR1CNR2 | |
| SCHEMBL6685602 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRHTTTAS1R3TAS1R1 | |
| SCHEMBL6085186 | 0.81 | CNR1 (0.60) | ALDH1A1TSHRHTTKDM4ETAS1R3 | |
| SCHEMBL12505792 | 0.78 | HTT (0.80) | ALDH1A1TSHRHTTKDM4ETAS1R3 | |
| SCHEMBL29563786 | 0.77 | HTT (0.65) | ALDH1A1TSHRHTTKDM4ETAS1R3 | |
| SCHEMBL16691255 | 0.77 | ALDH1A1 (0.60) | ALDH1A1TSHRHTTKDM4ETAS1R3 | |
| SCHEMBL1018087 | 0.77 | SCN9A (0.48) | — | |
| SCHEMBL6637965 | 0.76 | ALDH1A1 (0.47) | ALDH1A1TSHRHTTTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | claimed |
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | disclosed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | disclosed |
| US-6534520-B2 | Antiviral compounds | BIOCHEM PHARMA INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | disclosed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | disclosed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | disclosed |
| EP-0984967-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC (CA) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | disclosed |
| WO-1997034894-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC. (CA) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031765-A1 | Antiviral compounds | ZC3HAV1, IFNAR1, EIF2AK2 | ALDH1A1 2126/4885TSHR 3652/4885HTT 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.